MGEN News and Press, Miragen Therapeutics Inc.

miRagen Therapeutics (MGEN) announced its name change to Viridian Therapeutics and ticker symbol 'VRDN'; to commence trading tomorrow.The company appointed Jonathan Violin, Ph.D., M.B.A. as President and CEO succeeding Lee Rauch who will remain as strategic advisor to the company; D...

Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...

miRagen Therapeutics (MGEN) inks an agreement to gain exclusive rights to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend Fc technology from Xencor.Under the terms of the license agreement, miRagen will be solely responsible for the activities and co...

Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...

Miragen has had years of disappointing share price performance with a cumulative loss of more than 90%. This is a reflection of the poor results in the two drug candidates that until recently composed its pipeline: Cobomarsen and Remlarsen. On October 28, the company wanted to mak...

Gainers: Phoenix Tree (DNK) +65%.Lexicon Pharmaceuticals (LXRX) +43%.Riot Blockchain (RIOT) +40%.Zomedica Pharmaceuticals (ZOM) +33%.Miragen Therapeutics (MGEN) +28%.AXT (AXTI) +27%.Glory Star New Media Group (GSMG) +26%.Yunhong CTI (CTIB) +23%.Kandi Technologies (KNDI) +22%.Se...

Gainers: Lexicon Pharmaceuticals (LXRX) +45%, Zomedica Pharmaceuticals (ZOM) +33%, Miragen Therapeutics (MGEN) +17%, SQZ Biotechnologies (SQZ) +15%, PLx Pharma (PLXP) +13%.Losers: Brainstorm Cell Therapeutics (BCLI) -67%, GoodRx Holdings (GDRX) ...

Miragen Therapeutics (MGEN): Q3 GAAP EPS of -$0.10 beats by $0.03.After the Viridian Therapeutics deal, the company has cash on hand of ~$144M and estimated cash runway through 2023.Press Release For further details see: Miragen Therapeutics EPS beats by $0.03

Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...

RealNetworks (RNWK) -12% on Q3 earnings release.Aptevo Therapeutics (APVO) -12%.vTv Therapeutics (VTVT) -8% on reporting baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzhe...